The application belongs to the field of biological
medicine research and development, and particularly relates to application of
umbilical cord mesenchymal stem cell-derived vascular endothelial precursor cells in preparation of medicines for preventing and treating atherosclerosis. By interfering with expression of
related factors in a
pyroptosis inflammatory signaling pathway of NLRP3, ASC,
Caspase-1, GSDMD, IL-1β and IL-18 at a transcription and
protein level, the serum
triglyceride concentration,
total cholesterol concentration and low-density
lipoprotein concentration can be reduced, the serum oxidized low-density
lipoprotein and
oxygen free radical concentration can be reduced, the serum high-density
lipoprotein concentration can be increased, and the atherosclerotic
plaque area can be reduced and
cell apoptosis in the atheromatous plaque can be inhibited.